Key terms

About XFOR

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest XFOR news

Yesterday 7:56am ET X4 Pharmaceuticals announces $125M capital infusion by TipRanks Yesterday 7:13am ET X4 Pharmaceuticals Advances with Strategic Financial Moves by TipRanks May 02 11:10am ET Biotech Alert: Searches spiking for these stocks today by TipRanks May 01 10:51am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Apr 30 6:20am ET Buy Rating Affirmed for X4 Pharmaceuticals’ Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy by TipRanks Apr 30 6:04am ET X4 Pharmaceuticals price target raised to $5 from $3 at H.C. Wainwright by TipRanks Apr 29 11:36am ET X4 Pharmaceuticals’ Xolremdi approved for WHIM syndrome, says Cantor Fitzgerald by TipRanks Apr 29 9:40am ET Unusually active option classes on open April 29th by TipRanks Apr 29 6:31am ET X4 Pharmaceuticals announces FDA approval of XOLREMDI capsules by TipRanks Apr 26 10:52am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Apr 01 9:32am ET X4 Pharmaceuticals Updates Corporate Presentation Online by TipRanks Mar 23 2:01am ET X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence by TipRanks Mar 22 6:28am ET Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects by TipRanks Mar 21 6:02am ET X4 Pharmaceuticals reports Q4 EPS (10c), consensus (15c) by TipRanks Mar 18 8:00am ET Options Volatility and Implied Earnings Moves This Week, March 18 – March 21, 2024 by TipRanks Feb 29 10:32am ET X4 Pharmaceuticals management to meet with Cantor Fitzgerald by TipRanks

No recent press releases are available for XFOR

XFOR Financials

1-year income & revenue

Key terms

XFOR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

XFOR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - MAY 03: Traders work on the floor of the New York Stock Exchange (NYSE) on May 03, 2024 in New York City. The Dow surged over 400 points in morning trading as new economic numbers showed that the central bank may cut interest rates sooner than expected. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images North America/Getty Images
There’s a surprising bit of good news lurking in the stock market
Bruce Garelick was found guilty of insider trading
John Minchillo/AP
Investor found guilty in Trump Media insider trading case
People walk toward an entrance to Disneyland in Anaheim, California on April 24, 2023.
Mario Tama/Getty Images/File
Americans are shopping less but they’re still spending on flights, hotels and Disneyland
Scaffolding and construction netting near an apartment building in New York, US, on Wednesday, Oct. 11, 2023. Monthly fees and expenses for inspections, insurance and climate-friendly upgrades are squeezing residents of the city's many co-op and condo buildings. Photographer: Michael Nagle/Bloomberg
Michael Nagle/Bloomberg/Getty Images
For US renters, the chance of owning a home is going from bad to worse